• Directory
  • Search
  • All results
  • Journals
  • Definitions
Immunologic Factor
Ustekinumab
An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to... NCI Thesaurus more
An orally available, human, IgG1kappa, monoclonal antibody directed against the p40 protein subunit of both interleukin-12 (IL-12) and IL-23, with immunomodulating activity. Upon administration, ustekinumab binds to the p40 subunit of IL-12 and IL-23, blocking the binding of IL-12 and IL-23 to their interleukin receptors. This inhibits IL-12- and IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent graft versus host disease (GVHD). IL-12 and IL-23, cytokines that play a key role in the regulation of the immune system, are upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD. NCI Thesaurus
Brand Names:
Stelara
May Treat:
Arthritis, Psoriatic; Crohn Disease
Group:
Antibodies, Monoclonal, Humanized
Mechanism:
Interleukin-12 Antagonists; Interleukin-23 Antagonists
More Information:
ChemID; DrugBank; DailyMed; DrugInfo; PDR
Always consult a medical professional for advice (Terms) Use Notice Feedback Sources
Logo
ustekinumab
Medscape
Stelara (ustekinumab) dosing, indications, interactions, adverse effects, and more.
Definitions:
Ustekinumab
NLM Medical Subject Headings
A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.
Ustekinumab
NLM Medical Subject Headings
A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.
Related topics:
adalimumab
alemtuzumab
bevacizumab
certolizumab pegol
cetuximab
denosumab
more...
Related terms:
adalimumab
alemtuzumab
bevacizumab
certolizumab pegol
cetuximab
denosumab
ipilimumab
natalizumab
omalizumab
palivizumab
ranibizumab
trastuzumab
Viewing results 1 - 10 of 837,000 (0.26 seconds)
  • Ustekinumab Injection: MedlinePlus Drug Information
    Ustekinumab injection is used to treat moderate to severe plaque psoriasis (skin disease in which red, scaly patches form on some areas of the body) in ...
    medlineplus.gov/druginfo/meds/a611013.html
  • Stelara (ustekinumab) dosing, indications, interactions, adverse ...
    USES: Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis (psoriatic arthritis), or certain bowel conditions (Crohn's disease, ulcerative ...
    reference.medscape.com/drug/stelara-ustekinumab-345050
  • Bimekizumab versus ustekinumab for the treatment of moderate to ...
    Feb 6, 2021 ... We aimed to compare the efficacy and safety of bimekizumab with placebo and ustekinumab in patients with moderate to severe plaque psoriasis ...
    thelancet.com/journals/lancet/article/PIIS0140...2/fulltext
  • Ustekinumab Induction and Maintenance Therapy in Refractory ...
    Oct 18, 2012 ... Background In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and ...
    nejm.org/doi/full/10.1056/nejmoa1203572
  • How to Optimize Treatment With Ustekinumab in ... - Frontiers
    Jan 28, 2021 ... How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Ana ...
    frontiersin.org/articles/10.3389/fmed.2021.640813/full
  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in ...
    Oct 1, 2015 ... BackgroundEarly clinical studies suggested that the anti–interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the ...
    nejm.org/doi/full/10.1056/nejmoa1503824
  • Ustekinumab: Uses, Interactions, Mechanism of Action | DrugBank ...
    Ustekinumab is a targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, ...
    go.drugbank.com/drugs/DB05679
  • Association Between Early Severe Cardiovascular Events and the ...
    Sep 9, 2020 ... Importance Ustekinumab, a monoclonal antibody targeting interleukin 12/23p40 (IL-12/23p40), is effective in the treatment of moderate to severe ...
    jamanetwork.com/journals/jamadermatology/fullarticle/2770560
  • S0855 Efficacy of Ustekinumab in Ileum-Dominant vs Colonic C ...
    This real-world experience on ustekinumab therapy demonstrates a difference in mucosal healing rates between ileum-dominant and colonic CD. Numerically, there ...
    journals.lww.com/.../s0855_efficacy_of_ustekinumab_in_ileum_ dominant_vs.856.aspx
  • Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of ...
    Mar 27, 2019 ... This cohort study compares the risk of developing atrial fibrillation or major adverse cardiovascular events associated with ustekinumab vs ...
    jamanetwork.com/journals/jamadermatology/fullarticle/2729075
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next >
Try this search on: Bing, Google Scholar, or PubMed
  • About
  • Feedback
  • Guides
  • Terms
© 2022 www.medicalphysicist.co.uk
The content on this site is NOT a substitute for professional medical advice or diagnosis. Always seek the advice of your doctor or health care provider.